ArticleAntibiotics (Basel, Switzerland)2022
Genomic and Phenotypic Characterization of
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Pooled it
- Pseudolysogeny-mediated evolutionary trade-offs favor phage therapy by limiting antibiotic resistance and virulence in Cutibacterium acnes.Scientific reports · 2026Article
- Isolation and Genomic Characterization of Two LyticViruses · 2026Article
- Characterisation of the NovelInternational journal of molecular sciences · 2025Article
- Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Characterization of the novel Cutibacterium acnes phage KIT08 and its associated pseudolysogenic bacterial isolate.Archives of microbiology · 2025Article
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- Therapeutic Phage Candidates for Targeting Prevalent Sequence Types of Carbapenem-ResistantFoodborne pathogens and disease · 2024Article
- Can Gentisic Acid Serve as a High-Performance Antioxidant with Lower Toxicity for a Promising New Topical Application?Life (Basel, Switzerland) · 2024Article
- The Microbiome and Acne: Perspectives for Treatment.Dermatology and therapy · 2024Review
- Bacteriophage as a novel therapeutic approach for killing multidrug-resistantFrontiers in microbiology · 2024Article
- Article
- Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes.Scientific reports · 2023Article
- Topical phage therapy in a mouse model of Cutibacterium acnes-induced acne-like lesions.Nature communications · 2023Article
- Recent development in the preservation effect of lactic acid bacteria and essential oils on chicken and seafood products.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cutibacterium acnes is a pathogen that can cause acne vulgaris, sarcoidosis, endodontic lesions, eye infections, prosthetic joint infections, and prostate cancer. Recently, bacteriophage (phage) therapy has been developed as an alternative to antibiotics. In this study, we attempted to isolate 15 phages specific to C. acnes from 64 clinical samples obtained from patients with acne vulgaris. Furthermore, we sequenced the genomes of these three phages. Bioinformatic analysis revealed that the capsid and tape measure proteins are strongly hydrophobic. To efficiently solubilize the phage particles, we measured the adsorption rate, one-step growth curve, and phage stability using an SMT2 buffer containing Tween 20. Here, we report the genotypic and phenotypic characteristics of the novel C. acnes-specific phages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.